Patents Represented by Attorney William C. Martens
  • Patent number: 4100117
    Abstract: The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically-acceptable acid addition salts exhibit various activities including inhibition of the release of gastric acid and reduction of gut motility.
    Type: Grant
    Filed: April 21, 1977
    Date of Patent: July 11, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4093574
    Abstract: The tetradecapeptides ##STR1## in which Y is L-Asn or L-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. These tetradecapeptides as well as their pharmaceutically-acceptable acid addition salts exhibit various activities including inhibition of the release of gastric acid.
    Type: Grant
    Filed: February 2, 1977
    Date of Patent: June 6, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4093800
    Abstract: A novel 4-(2'-benzothiazolyldithio)-3-imidoazetidin-2-one of the formula ##STR1## in which X is chloro or bromo and R.sub.2 is methylene or oxygen is ring-closed to the corresponding 3-exomethylenecepham or 3-"oxo" cepham by treatment with sodium or potassium iodide at a temperature of from about 40.degree. C. to about 80.degree. C.
    Type: Grant
    Filed: February 14, 1977
    Date of Patent: June 6, 1978
    Assignee: Eli Lilly and Company
    Inventor: Stjepan Kukolja
  • Patent number: 4087390
    Abstract: The tetradecapeptides ##STR1## in which Y is L-Asn or L-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. These tetradecapeptides as well as their pharmaceutically-acceptable acid addition salts exhibit various activities including inhibition of the release of gastric acid.
    Type: Grant
    Filed: February 2, 1977
    Date of Patent: May 2, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4087444
    Abstract: N-[2-(5-methoxy-6-haloindol-3-yl)ethyl]amides are valuable, orally active, ovulation inhibitors.
    Type: Grant
    Filed: September 8, 1976
    Date of Patent: May 2, 1978
    Assignee: Eli Lilly and Company
    Inventors: Michael E. Flaugh, James A. Clemens
  • Patent number: 4082766
    Abstract: N-Chlorophthalimide is prepared by contacting an alkali metal salt of phthalimide with chlorine under substantially non-aqueous conditions in the presence of a halogenated aliphatic hydrocarbon and at a temperature of from about -10.degree. C. to about +40.degree. C.
    Type: Grant
    Filed: May 27, 1976
    Date of Patent: April 4, 1978
    Assignee: Eli Lilly and Company
    Inventors: Ta-Sen Chou, James R. Burgtorf
  • Patent number: 4082627
    Abstract: Dihydrobenzopyranoxanthenones of the formula ##STR1## are electrolytically reduced to their corresponding hexahydrobenzopyranoxanthenones at a mercury cathode in the presence of a proton source and in the presence of an electrolyte selected from the group consisting of alkali metal salts, quaternary ammonium salts having a total of about 10 to about 28 carbon atoms in the cation moiety, and tertiary amine salts having a total of about 7 to about 21 carbon atoms in the cation moiety.
    Type: Grant
    Filed: May 26, 1977
    Date of Patent: April 4, 1978
    Assignee: Eli Lilly and Company
    Inventors: David A. Hall, Richard E. Heiney
  • Patent number: 4081458
    Abstract: Compounds of the formula ##STR1## in which each R is hydrogen, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, hydroxy, cyano, or halo, and both R groups are identical and are symmetrically located; R.sub.1 is C.sub.1 -C.sub.3 alkyl and R.sub.2 is methyl, or R.sub.1 and R.sub.2 taken together are (CH.sub.2 --.sub.n in which n is an integer from 4 to 6; and (1) X.sub.c and X.sub.d are hydrogen, and the combination of X.sub.a and Y.sub.a and of X.sub.b and Y.sub.b each represents a double bond, subject to the limitation that, when R.sub.1 is C.sub.1 -C.sub.3 alkyl and is other than methyl, X.sub.c, X.sub.d, and R.sub.1 are all in an .alpha.-configuration; or (2) X.sub.a, X.sub.b, X.sub.c, X.sub.d, Y.sub.a, and Y.sub.b are hydrogen, subject to the limitation that both X.sub.c and X.sub.d are in an .alpha.-configuration, both X.sub.a and X.sub.b are in an .alpha.-configuration or in a .beta.-configuration, and, R.sub.1, when it is C.sub.1 -C.sub.3 alkyl, is in an .alpha.
    Type: Grant
    Filed: May 26, 1977
    Date of Patent: March 28, 1978
    Assignee: Eli Lilly and Company
    Inventor: Michael E. Flaugh
  • Patent number: 4081440
    Abstract: A penicillin sulfoxide ester is reacted with an N-chloro halogenating agent at a temperature of from about 75.degree. C. to about 135.degree. C. to produce a novel 2-chlorosulfinylazetidin-4-one intermediate. The intermediate can be treated with stannic chloride to produce a 3-exomethylenecepham sulfoxide.
    Type: Grant
    Filed: April 2, 1976
    Date of Patent: March 28, 1978
    Assignee: Eli Lilly and Company
    Inventor: Stjepan Kukolja
  • Patent number: 4076659
    Abstract: The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically acceptable acid addition salts inhibit the release of growth hormone and the release of gastric acid.
    Type: Grant
    Filed: March 17, 1976
    Date of Patent: February 28, 1978
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4075223
    Abstract: Derivatives of 2-aroyl-3-phenylindenes, 3-aroyl-4-phenyl-1,2-dihydronaphthalenes, and 1-phenyl-2-aroyl-naphthalenes are useful as antifertility agents.
    Type: Grant
    Filed: November 24, 1976
    Date of Patent: February 21, 1978
    Assignee: Eli Lilly and Company
    Inventors: Tulio Suarez, C. David Jones
  • Patent number: 4075203
    Abstract: A penicillin sulfoxide ester is reacted with an N-chloro halogenating agent at a temperature of from about 75.degree. C. to about 135.degree. C. and in the presence of an alkylene oxide and calcium oxide to produce a 2-chlorosulfinylazetidin-4-one intermediate. The intermediate, upon separation from the alkylene oxide, calcium oxide, and any conversion products of both the alkylene oxide and calcium oxide, can be treated with stannic chloride to produce a 3-exomethylenecepham sulfoxide.
    Type: Grant
    Filed: June 16, 1976
    Date of Patent: February 21, 1978
    Assignee: Eli Lilly and Company
    Inventor: Ta-Sen Chou
  • Patent number: 4075227
    Abstract: Derivatives of 2-aroyl-3-phenylbenzothiophenes and 2-aroyl-3-phenylbenzothiophene-1-oxides are useful as antifertility agents.
    Type: Grant
    Filed: November 22, 1976
    Date of Patent: February 21, 1978
    Assignee: Eli Lilly and Company
    Inventors: C. David Jones, Tulio Suarez
  • Patent number: 4062816
    Abstract: The tetradecapeptide ##STR1## is described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptide. This tetradecapeptide as well as its pharmaceutically acceptable acid addition salts inhibit the secretion of gastric acid.
    Type: Grant
    Filed: March 11, 1976
    Date of Patent: December 13, 1977
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4061607
    Abstract: The tetradecapeptides ##STR1## in which Y is L-Cha, L-Leu, or D-Phe are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. These tetradecapeptides as well as their pharmaceutically-acceptable acid addition salts inhibit the release of growth hormone.
    Type: Grant
    Filed: July 28, 1976
    Date of Patent: December 6, 1977
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4061626
    Abstract: The tetradecapeptides ##STR1## in which Y is Gly or D-Ala are described along with corresponding non-toxic pharmaceutically-acceptable acid addition salts as well as intermediates useful in the synthesis of the tetradecapeptides. The tetradecapeptide in which Y is Gly as well as its pharmaceutically acceptable acid addition salts exhibit as their principal activity the in vivo inhibition of the release of gastric acid. The tetradecapeptide in which Y is D-Ala as well as its pharmaceutically acceptable acid addition salts exhibit as their principal activity the in vivo stimulation of the release of growth hormone.
    Type: Grant
    Filed: April 29, 1976
    Date of Patent: December 6, 1977
    Assignee: Eli Lilly and Company
    Inventor: James E. Shields
  • Patent number: 4061861
    Abstract: Cephalosporin antibiotics of the formula ##STR1## in which, for example, R is phenyl, hydroxyphenyl, halophenyl, thienyl, or furyl; R.sub.1 is hydrogen, carbamoyloxy, acetoxy, a lower alkyl substituted 1H-tetrazol-5-ylthio or 1,3,4-thiadiazol-5-ylthio group; and R.sub.2 is hydrogen or methyl; are highly active broad spectrum antibiotics especially useful in the treatment of infections attributable to the gram-negative microorganisms.
    Type: Grant
    Filed: June 21, 1976
    Date of Patent: December 6, 1977
    Assignee: Eli Lilly and Company
    Inventor: William H. W. Lunn
  • Patent number: 4056676
    Abstract: Certain halogenated phenylthioacetamido cephalosporanic acids and derivatives thereof, e.g., 7-[2'-(2",5"-dichlorophenylthio)acetamido]cephalosporanic acid, are effective antibiotics against Staphylococcus aureus cultures which show heterogeneous resistance to methicillin.
    Type: Grant
    Filed: June 9, 1975
    Date of Patent: November 1, 1977
    Assignee: Eli Lilly and Company
    Inventor: George W. Huffman
  • Patent number: 4056519
    Abstract: The proteinase plasmin is assayed either colorimetrically or fluorometrically with a tripeptidyl-4-methoxy-2-naphthylamide substrate having the following general formula: ##STR1## The substrate is useful for either routine clinical assays or kinetic studies.
    Type: Grant
    Filed: May 10, 1976
    Date of Patent: November 1, 1977
    Assignee: Eli Lilly and Company
    Inventors: Jesse L. Bobbitt, Edward L. Smithwick, Jr.
  • Patent number: 4048161
    Abstract: Cephalosporin antibiotics of the formula ##STR1## in which, for example, R is phenyl, hydroxyphenyl, halophenyl, thienyl, or furyl; R.sub.1 is hydrogen, carbamoyloxy, acetoxy, a lower alkyl substituted 1H-tetrazol-5-ylthio or 1,3,4-thiadiazol-5-ylthio group; and R.sub.2 is hydrogen, C.sub.1 -C.sub.3 alkyl, C.sub.1 -C.sub.3 alkoxy, chloro, bromo, or fluoro; are highly active broad spectrum antibiotics especially useful in the treatment of infections attributable to the gram-negative microorganisms.
    Type: Grant
    Filed: May 20, 1976
    Date of Patent: September 13, 1977
    Assignee: Eli Lilly and Company
    Inventors: William H. W. Lunn, Edward V. Mason